Compare Koninklijke Philips NV (PHG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Tango Therapeutics Inc. — how do they compare? Koninklijke Philips NV trades at $25.17 (market cap $24.60B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Koninklijke Philips NV is far larger — about 6.6× Tango Therapeutics Inc.'s market cap, and Koninklijke Philips NV pays a 4.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| PHG | TNGX | |
|---|---|---|
Market Cap | $24.60B | $3.74B |
Volume | 1,105,836 | 3,438,781 |
Sector | Health | Health |
52-Week High | $32.91 | $32.90 |
52-Week Low | $23.81 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $30.96B | $2.76B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.89, up 0.61% with a bullish technical signal despite mixed momentum indicators. The company shows strong earnings momentum with three consecutive quarterly beats and a return to profitability in 2025 after previous losses. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care. Valuation metrics appear reasonable with P/E of 19.49 and P/S of 1.22.
The outlook remains cautiously optimistic with improving fundamentals but faces execution risks in a competitive healthcare technology market. Analyst consensus leans Hold (63.64%) with no Sell ratings, suggesting stable but not aggressive growth expectations. Key risks include cybersecurity vulnerabilities highlighted by recent hacking incidents and the need to maintain innovation leadership against larger competitors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
